Using 18F-FDG PET/CT to Estimate the Length of Gross Tumor and Involvement of Lymph Nodes in Esophagogastric Junction Carcinoma

Author(s):  
C.L. Ma ◽  
Y.H. Yu ◽  
X.D. Li ◽  
Y. Zhang ◽  
J. Li ◽  
...  
2018 ◽  
Vol 43 (12) ◽  
pp. 936-938
Author(s):  
Qingqing Pan ◽  
Yaping Luo ◽  
Jian Li ◽  
Shu Zhang ◽  
Fang Li

2019 ◽  
Vol 58 (01) ◽  
pp. 17-22
Author(s):  
Paulina Cegla ◽  
Bartosz Urbanski ◽  
Ewa Burchardt ◽  
Andrzej Roszak ◽  
Witold Cholewinski

Abstract Aim Cervical cancer is one of the most common cancers of the female reproductive system. The aim of the study was to assess the usefulness of the 18F-FDG-PET/CT study in staging of cervical cancer, with focus on the primary tumor parameters. Material & Methods 105 patients (mean age 56 ± 11y) with newly diagnosed cervical cancer underwent PET/CT examination which was performed 60 min after IV injection of 18F-FDG with a mean activity of 364 ± 75MBq. 68 patients were diagnosed with stage IIIA/IIIB, 19 patients with IIB, 10 patients with IB, 8 patients with stage IVA/IVB. Wilcoxon-Mann-Whitney test and ROC curves were used for statistical analysis. Results In 35 cases 18F-FDG-PET/CT did not show active proliferative process outside the cervix. In 38 cases metastases were found in iliac lymph nodes and in 32 patients scans showed metastases above the aortic bifurcation including lymph nodes and other organs. The largest volumes of primary tumor occurred in patients with distant metastases, while the lowest in patients with disease limited only to cervix. In 63 % of the patients PET/CT result was compatible with FIGO classification, in 20 % patients PET/CT result showed less advanced disease and in 17 % of the patients PET/CT results were higher than FIGO classification. Conclusion PET/CT using 18F-FDG has an important impact on the assessment of the stage of cervical cancer. In over 30 % of patients, this study resulted in a radical change in the treatment plan.


2017 ◽  
Vol 12 (1) ◽  
pp. S594-S595
Author(s):  
Ruta Vosyliute ◽  
Gabija Visockyte ◽  
Donatas Vajauskas

2018 ◽  
Vol 27 (2) ◽  
pp. 66-72 ◽  
Author(s):  
Özge Vural Topuz ◽  
Fatma Arzu Görtan ◽  
Zübeyde Rana Kaya Döner ◽  
Çetin Önsel ◽  
Haluk Burçak Sayman

2021 ◽  
Vol 46 (5) ◽  
pp. 433-434
Author(s):  
Gary A. Ulaner ◽  
Peter Giuliano
Keyword(s):  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  

2020 ◽  
Vol 9 (9) ◽  
pp. 2715
Author(s):  
Reyhaneh Manafi-Farid ◽  
Alexander Kupferthaler ◽  
Helwig Wundsam ◽  
Georg Gruber ◽  
Reza Vali ◽  
...  

Accurate staging and treatment planning are imperative for precise management in Anal Cancer (ACa) patients. We aimed to evaluate the additive and prognostic value of pre-treatment 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (2-[18F]FDG PET/CT) in the staging and management of ACa compared to magnetic resonance imaging (MRI). This retrospective study was conducted on 54 patients. Pre-treatment 2-[18F]FDG PET/CT studies and MRI reports were compared considering the primary tumor, pelvic lymph nodes, and metastatic lesions. The impact of 2-[18F]FDG PET/CT in the management and its prognostic value, using maximum standardized uptake value (SUVmax), were assessed. Discordant findings were found in 46.3% of patients (5 in T; 1 in T and N; 18 in N; and 1 in M stage). 2-[18F]FDG PET/CT resulted in up-staging in 9.26% and down-staging in 3.7% of patients. Perirectal lymph nodes were metabolically inactive in 12.9% of patients. Moreover, 2-[18F]FDG PET/CT resulted in management change in 24.1% of patients. Finally, SUVmax provided no prognostic value. 2-[18F]FDG PET/CT altered staging and management in a sizable number of patients in this study, and supports a need for a change in guidelines for it to be used as a routine complementary test in the initial management of ACa.


Sign in / Sign up

Export Citation Format

Share Document